The atheroprotective role of apolipoprotein E (apoE) is well established. During inflammation, expression of apoE in macrophages is reduced leading to enhanced atheromatous plaque development. In the present study, we investigated the signaling pathways involved in the repression of apoE gene expression in response to lipopolysaccharide (LPS) treatment, a condition that mimics the inflammatory stress, in mouse macrophages RAW 264.7. We identified Tpl-2 and MEKK1 as the kinases that are primarily responsible for the downregulation of apoE promoter activity by LPS. Using a dominant negative form of IκB, we established that Tpl-2 and MEKK1 signaling pathways converge to NF-κB acting on the apoE core promoter -55/+73. In addition to NF-κB activation, LPS also activated c-Jun via its phosphorylation by JNK. The activity of the apoE promoter was repressed by c-Jun whereas siRNA-mediated inhibition of endogenous c-Jun expression reversed the inhibitory effect of Tpl-2 on the apoE promoter. Transfection experiments and DNA binding assays showed that the binding site for c-Jun is in the -55/+73 region of the apoE promoter. Finally, we showed that LPS inhibited apoE gene expression via activation of the Tpl-2/MEK/ERK pathway acting on a different apoE promoter region. In summary, LPS represses apoE gene expression in macrophages via signaling pathways that involve the upstream kinases Tpl-2 and MEKK1, the intermediate MAP kinases ERK and JNK and the downstream transcription factors AP-1 and NF-κB that inhibit the apoE promoter activity via distinct regions.
The atheroprotective role of apolipoprotein E (apoE) is well established. During inflammation, expression of apoE in macrophages is reduced leading to enhanced atheromatous plaque development. In the present study, we investigated the signaling pathways involved in the repression of apoE gene expression in response to lipopolysaccharide (LPS) treatment, a condition that mimics the inflammatory stress, in mouse macrophages RAW 264.7. We identified Tpl-2 and MEKK1 as the kinases that are primarily responsible for the downregulation of apoE promoter activity by LPS. Using a dominant negative form of IκB, we established that Tpl-2 and MEKK1 signaling pathways converge to NF-κB acting on the apoE core promoter -55/+73. In addition to NF-κB activation, LPS also activated c-Jun via its phosphorylation by JNK. The activity of the apoE promoter was repressed by c-Jun whereas siRNA-mediated inhibition of endogenous c-Jun expression reversed the inhibitory effect of Tpl-2 on the apoE promoter. Transfection experiments and DNA binding assays showed that the binding site for c-Jun is in the -55/+73 region of the apoE promoter. Finally, we showed that LPS inhibited apoE gene expression via activation of the Tpl-2/MEK/ERK pathway acting on a different apoE promoter region. In summary, LPS represses apoE gene expression in macrophages via signaling pathways that involve the upstream kinases Tpl-2 and MEKK1, the intermediate MAP kinases ERK and JNK and the downstream transcription factors AP-1 and NF-κB that inhibit the apoE promoter activity via distinct regions.
Human apolipoprotein E (apoE), a glycoprotein of 35 kDa, plays a key role in lipid metabolism, as a major component of various plasma lipoprotein classes, including chylomicrons, very low density lipoproteins and large high density lipoproteins (1). As a ligand for the LDL receptor family, apoE scavenges lipoprotein remnants and mediates clearance of apoE-rich large HDL particles from the serum, a significant determinant of the redistribution of cholesterol and triglycerides between the peripheral tissues and the liver.
ApoE is mainly synthesized by the liver, kidney, lung, spleen, skin, brain and various cells such as macrophages (2) . ApoE production is of particular significance at sites endangered by the uptake of lipoproteins, such as the atheromatous plaques. The protective role of apoE in atherosclerosis was recognized in apoE KO mice, which is a well-established animal model for atherogenesis (3) . At the level of atheromas, macrophages are the primary providers of apoE. This was elegantly demonstrated in transgenic mice expressing apoE only in macrophages, which were protected from atherosclerosis, even though the plasma levels of apoE were exceedingly low and the animals were hypercholesterolemic (4) . Consistently, transgenic mice with normal levels of plasma apoE and apoE-null macrophages were more susceptible to atherosclerosis (5) . ApoE secretion by macrophages within the atherosclerotic plaque facilitates efflux of cholesterol to exogenous acceptors (such as HDL), assisting reversal of cholesterol transport to the liver.
The human apoE gene is 3.6 kb in length and is located on the chromosome 19, at the 5' end of the apoE/apoCI/apoCIV/apoCII gene cluster (6) . Transcriptional regulation of apoE requires the aggregation of several transcription factors on the proximal promoter. Several positive and negative elements have been detected on the apoE promoter (7) , including the AP-2, Zic1/Zic2 sites and the non-canonical E-box, which are important regulatory elements within the proximal apoE promoter in astrocytes (8-10). Transcription factors that drive the apoE expression in macrophages are not fully identified.
Currently, there is a general agreement that atherogenesis entails both a lipid disorder and an inflammatory process. The prominent role of inflammation in atherosclerosis (11) requires further elucidation of the molecular mechanisms at the level of the atherosclerotic plaque, which may lead to novel or more complex anti-inflammatory therapeutic targets. The aim of this study was to elucidate the regulatory mechanisms that control apoE promoter activity in macrophages in response to inflammatory signals. To mimic the inflammatory state, we used lipopolysaccharide (LPS), which activates numerous signal transduction cascades, including the NF-κB dependent production of inflammatory cytokines (12) . We report here that LPS represses apoE gene expression in macrophages. The mechanism involves Toll-like receptor-4 (TLR4)-mediated activation of the upstream kinases Tpl-2 and MEKK1, activation and nuclear translocation of the NF-κB and AP-1 transcription factors that act directly on the apoE promoter.
Experimental Procedures
Materials: Restriction and modification enzymes (T4 ligase, DNA polymerase, calf intestinal alkaline phosphatase) were purchased from Invitrogen (Invitrogen GmbH, Germany) or Promega corp. (Madison, WI). DMEM and fetal calf serum were from Invitrogen, Titan TM One Tube RT-PCR System from Roche (Basel, Switzerland), ECL Western blotting kit from Pierce (Rockford, USA); Luciferase assay system was from Promega; all other reagents were from Sigma Chemical Co (St. Louis, Mo). The primers were obtained from Invitrogen; siRNA for human c-Jun and all antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif.).
Plasmid constructions. The apoE proximal promoter (-500/+73) was cloned in the pGL3 basic vector (Promega) that contains as a reporter the promoterless luciferase (luc) gene. Briefly, the promoter sequence -500/+302 was amplified by PCR using the following primers: F : 5'  TTTGGTACCGCTGGTCTCAAACTCCTACCT  TAAGTGATTCG 3', R: 5' TTTAAGCT  TAACTCGTGGAGTCCTGCTATGGCTTACAT  CCC 3' After amplification, the DNA fragments were digested with KpnI and SacI (the apoE gene contains a SacI site at +73) and cloned in the pGL3-basic vector, obtaining the plasmid (-500/+73) apoE-luc.
The deletion mutants of the apoE promoter were obtained by PCR employing the following forward primers: F-100: 5'-GGGGTAC CACCTCGTGACTGGGGGCTG, F-55: 5'-GGGGTACCGGGGGCGGGACAGGGGGAG 3'. The reverse primer used was R+73: 5'-AAGAGCTCATCCCCGTGCCCCCG 3'. The amplified DNA fragments were digested with KpnI and SacI and cloned in the pGL3 vector obtaining the following plasmids (-100/+73) apoEluc and (-55/+73) apoE-luc.
The p(κB) 3 -luc contains three copies of an NF-κB site cloned upstream of the minimal simian virus 40 (SV40) promoter and the luciferase reporter gene in pGL2-Promoter (Promega).
The expression vectors for Tpl-2, Tpl-2DN, MEKK1 and MEK1 were a generous gift of Dr. Christos Tsatsanis (University of Crete Medical School, Heraklion, Greece). The expression vectors for IKKβ, p50/p65, c-Jun, JunB and JunD have been described previously (13, 14) . The expression vector for ERK2 was a generous gift of Dr. Didier Picard (University of Geneva, Geneva, Switzerland).
Cell culture. Mouse peritoneal macrophages (MPM) were isolated as previously described (15) . Briefly, 1.5-ml aliquot of 4% thioglycolate solution was injected intraperitoneally in BALB/c mice, and peritoneal macrophages were isolated by lavage of the peritoneal cavity with DMEM. MPM, RAW 264.7 and HEK293 cells were cultured in DMEM supplemented with 10% fetal calf serum, 100µg/ml penicillin and 100µg/ml streptomycin at 37°C in a 5% CO 2 incubator. One day prior transfection, RAW 264.7 cells were mechanically detached from the culture dish (employing a cell lifter) and plated in six well culture plates (0.8x10 6 cells /well). Monocytes U937 and THP-1 cell lines were grown in RPMI with 5% fetal bovine serum and antibiotics. (15) . Transiently transfected RAW 264.7 macrophages were treated for 18h with 1µg/ml LPS, alone or together with inhibitors (10µM U0126, 10µM cyclosporine, 10 nM PMA) Forty hours after transfection, the cells were harvested and subsequently lysed in the buffer included in the luciferase assay kit (Promega) followed by a freeze-thaw cycle and centrifugation at 13,000 rpm for 5 min. Luciferase assays were performed using the luciferase assay kit from Promega (as indicated by the manufacturer). The activity of β-galactosidase (βGal) was determined using o-nitrophenyl galactopyranoside.
DNA pull down assay: DNA fragments of the apoE promoter were biotinylated by PCR, using the corresponding apoE-luc plasmids as templates and the primers described for cloning except that the reverse primer (R+73) was biotinylated at the 5' end. In other experiments, biotinylated forward primer RVprimer3 (5´-CTAGCAAAATA GGCTGTCCC, Promega), and R+73 unbiotinylated were employed. In this case, the amplified product contained a fragment of 58 bp corresponding to the pGL3-basic vector. Biotinylated DNA was coupled to the Dynabeads M-280 Streptavidin according to the manufacturer's instructions. Briefly, biotinylated DNA was incubated with Dynabeads M-280 Streptavidin for 15 min at room temperature in B&W buffer (5 mM Tris-HCl, pH 7.5 with 0.5 mM EDTA and 1 M NaCl) in a slight excess of DNA. After coupling, the beads were washed twice with B&W buffer to remove the unbound DNA, and once with the binding buffer (see below). When RV3 primer was used, after immobilization of the DNA on Dynabeads, half of the total amount of the beads were treated with KpnI, to remove the (-55/+73) apoE fragment; the beads containing the 58bp from pGL3 vector were used as negative control for the DNA binding assay.
Nuclear extracts were purified as previously described (16) ; these extracts were incubated with the biotinylated DNA immobilized on Dynabeads for 90 min at 4°C in binding buffer (10 mM Hepes pH 7.9 with 50 mM KCl, 2 mM MgCl 2 , 4 mM spermidine, 0.1 mg/ml BSA, 20µM zinc acetate, 10% glycerol and 0.05% NP40). The complexes formed were isolated with Dynabeads M-280 Streptavidin, washed with binding buffer and then subjected to SDS PAGE followed by Western blotting, using anti-p50 or anti c-Jun antibodies. The blots were developed using an ECL kit from Pierce.
Immunoblotting. RAW 264.7 cells treated with LPS for various time intervals were washed with PBS, harvested, and solubilized in Laemmli buffer. The samples were subjected to SDS-PAGE, transferred onto nitrocellulose, and the blots were tested with the following antibodies: anti-ERK, anti-phospho-ERK, anti-phospho-SAPK, anti-c-Jun, anti-phospho c-Jun, and antip50. In other experiments, LPS treated cells were subjected to hypo-osmotic lysis using 7 mM phosphate buffer containing protease inhibitors (0.2mM PMSF and 1mM benzamidine). The cell homogenate was passed 10 times through a syringe needle (24G) and then centrifuged 10 min at 750g. The pellet containing the nuclear fraction was washed twice with PBS and solubilized in Laemmli buffer. The proteins from the supernatant, considered the cytoplasmic fraction, were precipitated with TCA (12% final concentration) and solubilized in Laemmli buffer. The protein concentration was determined using Amido Black (17) . From each sample, aliquots of 30 µg of protein were subjected to Western blot using the polyclonal antibodies anti-p50 and antic-Jun, followed by the secondary HRP-conjugated antibodies, which were revealed using an ECL kit (Pierce). The bands were quantified by densitometry using the Total Lab software Statistics. Values in the text are means ± SEM. One-way ANOVA was performed using OriginPro 7.5. For p values less than 0.05, the population means are statistically different.
RESULTS

LPS induces apoE gene expression in monocytes and inhibits apoE gene expression in macrophages.
To determine the effect of bacterial lipopolysaccharide (LPS) on the expression of apoE in monocytes and macrophages, we employed two monocytic cell lines (U937 and THP-1), a macrophage cell line (RAW 264.7) and thioglycollate-elicited mouse peritoneal macrophages (MPM). The cells were incubated with 1µg/ml LPS for 18h and apoE expression was determined by RT-PCR. The results showed a differential modulation of apoE by LPS in monocytes and macrophages. As illustrated in Figure 1A , apoE is expressed in both monocytic cell lines only in the presence of LPS. By contrast, this treatment decreased the basal levels of apoE mRNA in macrophage cell line by 30%, and in mouse peritoneal macrophages by 48%. Semiquantitative evaluation of the products obtained by RT-PCR showed a dose dependent repression of apoE in RAW264.7 cells by LPS treatment (for 18h). As compared with the control, the repression induced by LPS was statistically significant (p<0.035, Figure 1B ).
Inhibition of apoE gene expression by LPS involves kinases Tpl-2 and MEKK1.
To investigate the mechanism of apoE gene repression by LPS, the apoE proximal promoter (-500/+73) was cloned in front of the promoterless luciferase (luc) gene in the pGL3 basic vector. Determination of luciferase activity in transiently transfected RAW 264.7 macrophages revealed that LPS decreased drastically the activity of apoE promoter to 15±12% of the control value; (p<0.015, Figure 2A ).
Next, we focused on the characterization of the signaling pathways activated by LPS (downstream the Toll-like receptors) and searched for the exact region(s) of the apoE promoter that mediated inhibition by LPS in macrophages. For this purpose, cells were transiently transfected with reporter vectors encoding different apoE promoter fragments in conjunction with overexpression of kinases and nuclear factors previously shown to participate in LPS signaling.
Initially, we examined the role of Tpl-2 a serine threonine kinase that belongs to the MAP3 Kinases family in apoE gene regulation (18, 19) . As shown in Figure 2A , overexpression of Tpl-2 in macrophages suppressed the activity of the fulllength proximal (-500/+73) apoE promoter (41.7±19.3% relative to control, p<0.015). The dominant negative form of Tpl-2 (Tpl-2 DN) completely reversed the LPS induced suppression of apoE promoter activity ( Figure 2A) .
Then, we examined the effect of Tpl-2 on the activity of the two fragments of apoE promoter: (-100/+73) and (-55/+73) ( Figure 2B ). It is worth noting that the (-100/+73)apoE promoter fragment showed decreased reporter activity (to 39.2±8.9% of the full-length fragment) and the -55/+73 fragment was associated with further diminished activity (to 5.2±0,6% of the full-length fragment). Tpl-2 overexpression further reduced the activities of all apoE promoter fragments ( Figure 2B , black columns). These data indicated that the regulatory site is present in the smallest region of the proximal apoE promoter (-55/+73). Next, we tested the possible engagement of MEKK1 kinase in LPS-induced intracellular signaling that leads to apoE gene repression in macrophages. As shown in figure 2B (grey columns), MEKK1 overexpression decreased the activity of the (-500/+73) apoE promoter to 33.1±4.7% (p<0.015 vs control), of the (-100/+73) apoE promoter to 33.2±5.9% (p<0.02 vs control) and of the (-55/+73) apoE promoter to ~12.4±1.8% (p<0.01 vs control; Figure 2B , grey columns).
Taken together, the data presented in Figure 2 indicated that Tpl-2 and MEKK1 kinases, known to be involved in the LPS signaling pathways, repress apoE promoter activity in macrophages. The effective inhibitory site is contained within the shortest fragment of the apoE promoter tested here, namely the (-55/+73) region.
NF-κB is involved in LPS-induced apoE down-regulation and is a common downstream target of Tpl-2 and MEKK1
Next, we examined the involvement of the NF-κB pathway in the LPS-induced inhibition of apoE promoter activity in macrophages. For this purpose, we determined the nuclear and cytosolic distribution of the p50 subunit of NF-κB under LPS treatment. The Western blot data showed that the p50 precursor (p105) was present in the cytoplasmic fraction of untreated macrophages. After 3 hours of exposure to LPS, the p50 subunit was translocated to the nucleus, where it remained during the subsequent 18 hours of exposure to LPS. However, after 18 hours of LPS exposure, p105 (p50 precursor) reappeared in the cytosolic fraction ( Figure 3A) . Similar to the p50 subunit, tracking of the p65 subunit of NF-κB showed nuclear translocation after 3 hours of LPS treatment (data not shown).
Next, we evaluated whether NF-κB is involved in LPS induced suppression of apoE promoter.
Macrophages were transiently transfected with the (-500/+73) apoE promoter, along with Tpl-2 or MEKK1 in the presence or in the absence of a dominant negative form of IκB (IκBDN), and exposed to the LPS challenge. As illustrated in Figure 3B , the inhibitory effect of LPS on the (-500/+73) apoE promoter activity (columns 1 and 2) was reversed by the overexpression of IκBDN (column 3). Moreover, inhibition of apoE promoter activity by Tpl-2 and MEKK1 (columns 4 and 6, respectively), was completely reversed by IkBDN overexpression (columns 5 and 7, respectively).
The region of the apoE promoter that responds to NF-κB activation was investigated by transient transactivation assays. Macrophages were transfected with the three fragments of the apoE promoter and either wild type IKKβ kinase or a p50/65 hybrid. This hybrid is composed of the Rel homology domain (RHD) of p50 and the transactivation domain of p65. The hybrid is a constitutively active protein that simulates the active p50/65 heterodimer of NF-κB. Overexpression of either IKKβ kinase or the p50/65 hybrid abolished the activity of all apoE promoter fragments ( Figure 3C) , showing that the binding site for NF-κB is contained in the smallest apoE promoter fragment (-55/+73).
To validate the activation of the NF-κB pathway by the plasmids employed here, HEK293 cells were cotransfected with a vector containing three binding sites for NF-κB in sequence with the luciferase reporter gene [(NF-κB) 3 -luc]. In transfected cells, overexpression of Tpl-2, MEKK1 and IKKβ activated the (NF-κB) 3 promoter to various degrees ( Figure 3D ). By contrast, overexpression of MEK1 did not affect the activity of the (NF-κB) 3 promoter. These data demonstrate that NF-κB directly inhibits the apoE promoter and that the inhibitory effect of Tpl-2 and MEKK1 on the apoE promoter is mediated by their interference with the NF-κB pathway.
AP-1 transcription factors mediate the apoE promoter down-regulation by Tpl-2 in macrophages exposed to LPS
We next evaluated the role of AP-1 transcription factors in apoE gene regulation in response to LPS treatment. For this purpose, macrophages were homogenized after incubation with 1µg/ml LPS for variable periods of time, and probed using specific antibodies in Western blot experiments. Upregulated expression of c-Jun was noticed after a brief incubation (15 min) of the macrophages with LPS, and peak amounts were found after 60 min of incubation ( Figure 4A ). Phosphorylated c-Jun was consistently increased as early as 15 min following LPS addition and was decreased after prolonged incubation of the macrophages with LPS ( Figure  4A ). Phosphorylation of c-Jun implied early activation of Jun N-terminal Kinase (JNK), as observed by immunoblotting (data not shown). Activation of cJun depends on its translocation to the nucleus. In our experiments, an increase in the nuclear to cytosolic partition was directly related to the duration of macrophage incubation with LPS ( Figure 4A ). Thus, in LPS-treated macrophages, c-Jun is upregulated, phosphorylated and translocates to the nucleus.
Next, we investigated whether Tpl-2 and MEKK1 are responsible for c-Jun upregulation and phosphorylation by LPS. HEK293 cells were transfected with Tpl-2 or MEKK1 and c-Jun expression and phosphorylation were evaluated by immunoblotting. c-Jun expression was quantified by normalization against β-gal, cotransfected as an internal reference. Both Tpl-2 and MEKK1 induced c-Jun expression ( Figure 4B , lanes 2 and 4, respectively) as compared with the control cells ( Figure 4B, lane 1) . c-Jun induction by Tpl-2 and MEKK1 was decreased by ~50% after c-Jun silencing using siRNA ( Figure 4B, lanes 3 and 5,  respectively) . Moreover, we detected the phosphorylated form of c-Jun in cells overexpressing Tpl-2 and MEKK1 ( Figure 4B , lane 7 and 8, respectively), as compared with the control ( Figure 4B, lane 6) .
To determine whether c-Jun is involved in the downregulation of apoE promoter activity by Tpl-2 and MEKK1, cells were transiently transfected with an expression vector for Tpl-2 or MEKK1, the (-500+73) apoE-luc plasmid and a siRNA specific for c-Jun. Partial inhibition of c-Jun expression by siRNA ameliorated the inhibitory effect of Tpl-2 and MEKK1 on the apoE promoter ( Figure 4C ). The same results were obtained in RAW macrophages (not shown).
The inverse relationship between the amount of total or phosphorylated c-Jun and the apoE promoter activity strongly suggested that c-Jun is a central mediator of apoE promoter regulation by Tpl-2 and MEKK1. Consistent with the data related to NF-kB, the site of c-Jun mediated inhibition was identified in the shortest (-55/+73) apoE promoter fragment ( Figure 4D) .
To validate the binding of c-Jun to the (-55/+73) apoE promoter fragment, we performed DNA pull down experiments. In these assays, the apoE promoter fragments -445/+73 and -55/+73 were amplified by PCR using biotinylated primers and were incubated with nuclear extract of LPS treated RAW 264.7 macrophages. These experiments showed that both -445/+73 and -55/+73 apoE promoter fragments bind c-Jun ( Figure 4E, lanes 1 and 3, respectively) . Competition experiments, in which two times excess of unbiotinylated DNA was added (under the same experimental conditions), revealed the specificity of the binding ( Figure 4E, lanes 2 and  4) . Control experiments in which untreated RAW 264.7 cells were used under similar experimental conditions gave negative results (data not shown). In addition, another strategy was used to confirm the binding of c-Jun to the -55/+73 fragment of apoE promoter. The (-55/+73) apoE fragment was amplified by PCR using the plasmid (-55/+73) apoE-luc, as a template, and the biotinylated primer RV3 which corresponds to vector sequence and the reverse apoE +73 primer. This DNA fragment bound c-Jun present in LPS-treated nuclear extracts ( Figure 4E , lane 5), whereas no specific binding was detectable when the apoE promoter fragment was removed by KpnI digestion ( Figure 4E , lane 6).
MEK1/2 kinases are involved in the repression of the apoE promoter activity by Tlp2 in macrophages
We next determined the involvement of other kinases in apoE gene repression by LPS. We found that the repression in apoE gene expression by LPS in cultured mouse peritoneal macrophages (MPM) (to 57±4.6% relative to the control) was reversed by the specific MEK1/2 inhibitor U0126, as determined by RT-PCR. Furthermore, the MEK1 inhibitor counterbalanced very effectively the inhibition of apoE promoter activity by LPS in transiently transfected RAW 264.7 macrophages ( Figure 5B ). The data represent the average of the intensity of the bands corresponding to the apoE gene obtained by RT-PCR normalized to the expression levels of GAPDH, using MPM isolated from three mice.
To test whether MEK1 is a downstream target of Tpl-2 or MEKK1 in RAW 264.7 cells and mediates their negative effect on apoE promoter activity, RAW 264.7 cells were cotransfected with the plasmid (-500/+73) apoE-luc and the expression vectors for Tpl-2 ( Figure 5C ) or MEKK1 ( Figure 5D ) in the absence or presence of the inhibitor U0126. The results showed that the MEK1/2 inhibitor can only partially reverse the Tpl-2 repressive effect on the apoE promoter ( Figure 5C ), while the MEKK1 inhibitory activity on the apoE promoter was not affected by U0126 ( Figure 5D ). The same results were obtained using a different MEK1 inhibitor, PD98059 (data not shown).
Another downstream target known to be engaged in MEKK1 signaling (through SEK) is p38 (20). Cotransfection experiments in which an expression vector for p38 was used showed that overexpression of p38 did not influence the apoE promoter activity; moreover, the p38 inhibitor, SB203580, did not reverse the inhibitory activity of MEKK1 on the apoE promoter (data not shown).
In other experiments, we tested whether LPS can activate ERK1/2, a known downstream target of MEK1/2. For this purpose, RAW 264.7 macrophages were treated with 1µg/ml LPS for different time intervals and were tested for the ERK1/2 phosphorylation by immunoblotting using antibodies that recognize phosphorylated ERK. The results showed that ERK1/2 phosphorylation is an early response to the LPS treatment, and both isoforms, p44 and p42, were phosphorylated after 10 min of LPS exposure of the cells ( Figure 5E , lane 2) whereas the control (untreated) cells expressed only a very faint amount of phosphop42 ( Figure 5E , lane 1). Extended LPS treatment did not lead to the sustained activation of ERK1/2; at 1h of LPS treatment the amount of phospho-ERK1 and 2 significantly decreased ( Figure 5E , lane 3). To determine whether ERK1/2 is phosphorylated by MEK1/2, the RAW cells were treated with LPS for 10 min, in the presence or absence of the MEK1/2 inhibitor U0126. The results showed that ERK phosphorylation was dependent on MEK1/2, since the MEK inhibitor blocked the ERK phosphorylation by LPS ( Figure  5E , lane 4).
Transient transfection experiments were employed to search for the region in the apoE promoter that responds to ERK1/2 activation. The results illustrated in Figure 5F showed that the overexpression of the ERK2 inhibited the activity of the (-500/+73) apoE promoter in RAW 264.7 cells and this inhibition was drastically decreased by deletion of the region between -500 and -100. Thus, the region of the apoE promoter that responds to ERK2 activation is the -500 to -100.
DISCUSSION
ApoE has important functions in lipoprotein clearance and cholesterol redistribution, which counteracts atheroma formation. This protein is supplied to the atherosclerotic plaques primarily by macrophages locally differentiated. Accordingly, reduction or absence of macrophage synthesis of apoE promotes the development of atheromas. Within the atherosclerotic plaques, macrophages are often submitted to the inflammatory stress. In this study, we aimed to determine the molecular mechanisms of apoE gene suppression in macrophages under inflammatory stress mimicked by LPS treatment.
Previous studies have revealed that LPS has variable effects on apoE gene expression in different cell types. For example, in CaCo-2 epithelial cells, LPS represses apoE gene expression and apical secretion in a dose and time dependent manner (21) . LPS induces apoE gene expression in monocytes but represses gene expression in macrophages (Fig. 1) . Finally, apoE gene expression is induced by LPS in astrocytes (22 and Gafencu et al unpublished data). Thus, it seems that apoE gene regulation by LPS depends on the cellular context.
It has been reported previously that murine bone marrow-derived monocytic precursors do not synthesize apoE and that apoE gene expression is upregulated during macrophage maturation (23). In agreement with these findings, we show here that the monocytic lines THP-1 and U937 did not express apoE under basal conditions (Fig. 1B) . In sharp contrast, thioglycolate-induced peritoneal macrophages synthesized and secreted apoE (Fig.  1B) and this expression was repressed by LPS confirming previous reports of reduced apoE gene expression caused by bacterial endotoxins and other inflammatory agents (24) . Modulation of apoE gene expression by LPS was similar in both peritoneal macrophages and in RAW 264.7 cells, thus we focused on the RAW 264.7 cell line.
Through binding to the Toll-like receptor 4 (TLR-4), LPS activates intracellular signaling cascades that culminate in the expression of proinflammatory proteins (25) . For example, in macrophages, LPS is known to upregulate the proinflammatory protein COX-2 (27). Here we demonstrate that Tpl-2 is involved in downregulation of apoE, an anti-inflammatory factor. Thus, LPS may alter the balance between the proand anti-inflammatory molecules, leading to the aggravation of the atherogenic process.
The TLR-4 signaling pathway involves activation of the Tpl-2 protooncogene (26), a member of the mitogen activated protein kinase (MAPK) family. The serine/threonine kinase Tpl-2 (also known as Cot in humans) is a member of the MAP kinase kinase kinase (MAP3K) family, which regulates oncogenic and inflammatory pathways (18, 19) . Transcription factors activated by Tpl-2 include c-Jun, NF-κB and NF-AT (27).
We also found that MEKK1, another downstream target of TLR-4 activation (28), mimicked the modulation of the apoE gene expression by LPS in macrophages. As schematically illustrated in Figure 6 , the two kinases, Tpl-2 and MEKK1, are intercalated in the signaling pathway of TLR-4 that suppresses apoE gene expression. Our data revealed that NF-κB is a downstream target not only of Tpl-2, but also of MEKK1. This was demonstrated by using a dominant negative form of IκB (that does not detach from NF-κB) which abolished the effect of LPS and its downstream transcription factors Tpl-2 and MEKK1. (Fig. 3B, D) . In silico analysis revealed a potential NF-κB binding site at -43 of the apoE promoter (CONSITE -TF selection: http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite). The location of this NF-κB binding site close to the site of recruitment of the preinitiation complex suggested to us that this transcription factor may sterically inhibit the aggregation of certain components of the basal transcription apparatus. Thus, instead of increasing the promoter activity by positive interactions, the activation of these transcription factors inhibited promoter activity and downregulated gene expression. The surprising repressive effect of NF-κB on the apoE promoter corroborates a recent report showing that NF-κB mediates suppression of the cyp1a1 promoter by LPS (29) , and the inhibition of the APOC3 promoter by TNFα (30) .
Transfac analysis predicted NF-AT binding sites at the -297 and -313 of the apoE proximal promoter (31) . We recently observed translocation of NF-AT to the nucleus after brief exposure to LPS (not shown). However, neither a dominant negative form of NF-AT, nor cyclosporin reverted the inhibitory activity of Tpl-2 on the apoE promoter (data not shown). These data suggested that NF-AT is not involved in the apoE repression by LPS.
AP-1 is another transcription factor identified in this study to be involved in the apoE gene suppression by LPS. A recent study demonstrated that JNK-interacting protein 3 was involved in LPS-mediated JNK activation (32) . We have shown that c-Jun was activated following LPS treatment and bound to the apoE promoter in the -55/+73 region (Fig. 4) . The involvement of c-Jun on apoE gene transcription is further supported by recent findings showing that overexpression of a dominant negative c-jun in mice via adenovirusmediated gene transfer significantly elevated apoE mRNA levels in the liver as well as the plasma apoE levels (33) . In addition to the known positive role of c-Jun on gene activation, recent data revealed that AP-1 transcription factors participate in down-regulation responses. For example, TNFα suppresses the human Cu/Zn superoxide dismutase 1 promoter via the JNK/AP-1 signaling pathway (34). Interaction of c-Jun homodimers and heterodimers with other AP-1 partners bound to regulatory elements of the apoCIII promoter could mediate repression of apoCIII promoter activity (35) . Franklin et al. (36) revealed that the Cterminus of the c-Jun protein associates directly with TBP (TATA box-binding protein) and TFIIB in vitro, independently of c-Jun phosphorylation at the N-terminus. In our system, c-Jun recognized the apoE core promoter and inhibited its activity. This may suggest that binding of c-Jun to the proximal site of the apoE promoter may be stabilized by TBP, which interacts with an adjacent region.
An alternative mechanism of promoter inhibition by c-Jun is via inhibitory interactions with other transcription factors that bind to the same regulatory region. In this scenario, c-Jun could either bind directly to the DNA and inhibit the transcriptional activity of an adjacently bound factor or bind directly to the transcription factor without a requirement for direct DNA binding. In support of the latter scenario are the findings of Bilsland et al who showed that the MEKK1/JNK pathway represses human telomerase (hTR) gene expression by a mechanism that involves Sp1 and Sp3 (37) . The apoE promoter contains a GC-box at position -59/-45 that contains a perfect consensus recognition sequence for Sp1 factor (38) . Thus, it is possible that c-Jun is recruited to the proximal apoE promoter by Sp1 and inhibits transcription by interfering with the transactivation function of this transcription factor. In agreement with this hypothesis, no consensus AP-1 binding site (5' TGACTCA 3') was identified in the proximal apoE promoter (-500/+73).
In precursors of B cells and dendritic cells, NF-κB orchestrates the early effects of LPS signaling and controls subordinate activation of AP-1 that mounts the appropriate biological responses (39) . In macrophages, we have detected activation of AP-1 complexes as an early response to LPS (Fig. 4A) . By contrast, a late response to LPS treatment implicated NF-κB translocation to the nucleus beginning with 3h post LPS addition. Our experimental data revealed that NF-κB and AP-1 bind the apoE promoter adjacently to the TATA box suggesting the concerted action of these two transcription factors in the repression of apoE gene expression in macrophages. AP-1 and NF-κB may interfere with the functions of transcription factors that bind to the apoE promoter in the region -55/+73. This is in agreement with previous data revealing that the region including nucleotides -54 to -45 is required for maximum transcriptional activity of the apoE promoter (40) .
We also show here that activation of ERK by phosphorylation mediates inhibition of apoE gene expression by LPS (Fig. 5) . In addition, LPS activation of the MEK-ERK1/2 pathway in human monocytes induce Elk-1 phosphorylation and Egr-1 expression that upregulates tissue factor and TNFα expression (41) . These factors may also be involved in the apoE gene regulation in macrophages. Since the ERK-responsive region of the apoE promoter is distinct from the NF-κB and AP-1 sites, one can postulate that the repressive mechanisms of these transcription factors are different.
In conclusion, our results show that LPS downregulates the expression of apoE in macrophages at the level of transcription and inhibits the activity of the proximal apoE promoter. This effect is mediated by at least two upstream kinases, Tpl-2 and MEKK1, and subsequent activation of kinases IKKβ, JNK, MEK1/2 and ERK1/2, that activate NF-κB and AP-1 complexes ( Figure 6 ). These data imply that stress-associated factors reduce the expression of apoE in macrophages that reside in the atherosclerotic plaque. Since reduced apoE synthesis may aggravate the development of atheromas, the signaling proteins Tpl-2, MEKK1, NF-κB and c-Jun could be effective molecular targets for therapies aiming at the prevention of atheroma formation in human patients.
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We are indebted to Dr. C. Tsatsanis for his helpful suggestions and for providing RAW 264.7 cells and to Dr. Nadir Askenasy for useful critical remarks on the manuscript. We would like to thank Floarea Georgescu and Paraskevi Papakosta for excellent technical assistance. The abbreviations used are: apoE, apolipoprotein E; lipopolysaccharide, LPS; luc, luciferase; beta galactosidase, βGal; DMEM, Dulbecco's modified Eagle's medium. Fig. 1A, B . Modulation of apoE expression by LPS in monocytes and macrophages. Panel A. Two monocyte cell lines (U937 and THP1), a macrophage cell line (RAW 264.7), and mouse peritoneal macrophages (MPM) were used to determine the effect of LPS (1µg/ml for 18h) on apoE expression, by RT-PCR. GAPDH expression was measured to normalize the results. Panel B. Semiquantitative evaluation of the products obtained by RT-PCR showing a dose dependent repression of apoE in RAW264.7 cells by LPS treatment (for 18h). As compared with the control, the repression induced by LPS is statistically significant (p<0.04). Fig. 2A, B . Inhibition of apoE proximal promoter activity by Tpl-2 and MEKK1. Panel A. RAW macrophages were transiently cotransfected with 2 µg of the (-500/+73) apoE-luc plasmid along with 1 µg of CMV βGal plasmid and 2 µg of vectors expressing Tpl-2 wild type or dominant negative (Tpl-2 DN) in the presence or absence of LPS (1µg/ml for 18h). Forty hours following transfection, the cells were harvested and the luciferase activity was determined in the cell lysate. The mean values (±SEM) from at least two independent transfections, performed in duplicate are presented as bar graphs. Note that both, LPS and Tpl-2 inhibit the apoE promoter and this inhibition was activity statistically significant (p<0.015), whereas Tpl-2 DN reversed the LPS inhibition of apoE promoter activity. Panel B. RAW macrophages were transiently cotransfected with 2 µg of the apoE proximal promoter (-500/+73) apoEluc, as well as deletion mutants (-100/+73) apoE-luc and (-55/+73) apoE-luc in the absence or in the presence of expression vectors for Tpl-2 and MEKK1 (2 µg). The luciferase activity was normalized to the βGal activity. The results of these experiments showed that Tpl-2 and MEKK1 act on all the promoter fragments tested; the inhibitory action of Tpl-2 and MEKK1 on all the apoE promoter fragments tested was statistically significant ( p<0.05 for Tpl-2 and p< 0.02 for MEKK1). Assessment by Western blot of the presence of p50 subunit or its precursor (p105) in the cytoplasmic (C) and the nuclear fraction (N) obtained from macrophages exposed for various time intervals to 1µg/ml of LPS. Panel B. RAW macrophages were transiently cotransfected with 3 µg of the (-500/+73) apoE-luc plasmid along with 1 µg of CMV βGal plasmid and 1.5 µg of vectors expressing Tpl-2 wild type or MEKK1 in the presence or absence of a dominant negative form of IκB (IkBDN), and treated with 1µg/ml of LPS for 18 h or left untreated, as indicated. Forty hours following the transfection, the cells were harvested and the luciferase activity was determined in the cell lysate. The mean values (±SEM) from at least two independent transfections performed in duplicate are presented in the form of a bar graph. Note that IκBDN reverts the negative effects of LPS or of Tpl-2 and MEKK1 on apoE promoter activity. The difference in the activity of apoE promoter under LPS treatment or Tpl-2 and MEKK1 overexpression in the absence or in the presence of IκBDN overexpression was statistically significant (p<0.05). Panel C. RAW macrophages were transiently cotransfected with 2 µg of the apoE proximal promoter (-500/+73) apoE-luc or the deletion mutants (-100/+73) apoE-luc and (-55/+73) apoEluc in the absence or in the presence of expression vectors for IKKβ and for the p65/p50 hybrid of NF-κB (2 µg). The activity of the apoE promoter fragments was normalized to the βGal activity. Note that all apoE promoter fragments tested were inhibited by IKKβ and NF-κB (p<0.015 for IKKβ and p<0.03 for p65/50). Panel D. Activation of the NF-κB pathway in HEK293 cells by Tpl-2, MEKK1 and IKKβ. HEK293 cells were transfected with a plasmid containing three binding sites for NF-κB (NFκB 3 -luc, 2 µg) in the absence or in the presence of expression vectors for Tlp2, MEKK1 and IKKβ (2 µg). The normalized luciferase activity is shown in the form of a bar graph. Note that Tpl-2 as well as MEKK1 and IKKβ (p<0.01), but not MEK1 (p>0.8) increase the activity of the promoter containing three NF-κB binding sites. The data represent the average of three independent experiments using MPM isolated from three mice and were normalized to the expression levels of GAPDH. Panel B. Transient transfection in RAW 264.7 cells showed that MEK1 inhibitor (U0126) counterbalance the negative effect of LPS on apoE promoter activity. RAW 264.7 cells were transfected with the plasmid (-500/+73) apoE-luc in the absence or in the presence of LPS (1 µg/ml, 18h) or the specific MEK1 inhibitor U0126 (10µM, 18h). Cell lysates were analyzed for luciferase activity and the data are presented as a bar graph. Note that the MEK1 inhibitor U0126 reverted the repressive effect of LPS (p<0.01). Panel C. RAW 264.7 cells were cotransfected with the plasmid (-500/+73) apoE-luc alone (column 1) or together with expression vectors for Tpl-2 in the absence (column 2) or in the presence (column 3) of the MEK1/2 inhibitor (U0126). Cell lysates were analyzed for luciferase activity and the normalized (relative to βGal) data are presented as a bar graph. MEK1 inhibitor U0126 reverted the repressive effect of Tpl-2 (p<0.002). Panel D. RAW 264.7 cells were transiently transfected with the plasmid (-500/+73) apoE-luc (column 1) in the absence or in the presence of an expression vector for MEKK1 (column 2) and the MEK1 inhibitor U0126 (column 3). Cell lysates were analyzed for luciferase activity and the normalized (relative to βGal) data are presented as a bar graph. MEK1 inhibitor U0126 did not revert the repressive effect of MEKK1. There is no significant difference between the apoE promoter activity in the presence of MEKK1 overexpression alone or in the presence of U0126 (p>0.05). Panel E. Analysis of ERK1/2 phosphorylation in RAW macrophages treated with 1µg/ml LPS for different time intervals by Western blotting. Note that both ERK isoforms, p44 and p42, are phosphorylated after 10 min of LPS exposure of the cells (lane 2) whereas the control (untreated) cells expressed only a very faint amount of phospho-p42 (lane 1); at 1h of LPS treatment the amount of phospho-ERK1 and 2 are significantly decreased (lane 3). When RAW cells were treated with LPS for 10 min, in the presence or absence of U0126, ERK phosphorylation was inhibited (lane 4). Panel F. The -500/-100 region of the apoE promoter mediates the transcriptional repression by ERK. RAW 264.7 cells were transiently transfected with the (-500/+73) apoE-luc, (-100/+73) apoE-luc or (-55/+73) apoE-luc plasmids in the absence (light grey columns) or in the presence (dark grey columns) of an expression vector for ERK2. The normalized, relative luciferase activity of each promoter (± SEM) is shown in the form of a bar graph. Note that deletion of the -500/-100 region of the apoE promoter abolished the transcriptional repression by ERK2 (p<0.01). at FORTH Library on June 18, 2007 
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